nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—XDH—Cisplatin—germ cell cancer	0.416	0.463	CbGbCtD
Pyrazinamide—AOX1—Methotrexate—germ cell cancer	0.312	0.348	CbGbCtD
Pyrazinamide—CYP3A4—Ifosfamide—germ cell cancer	0.0583	0.0649	CbGbCtD
Pyrazinamide—CYP1A2—Etoposide—germ cell cancer	0.0532	0.0592	CbGbCtD
Pyrazinamide—CYP3A4—Vinblastine—germ cell cancer	0.0309	0.0344	CbGbCtD
Pyrazinamide—CYP3A4—Etoposide—germ cell cancer	0.0279	0.031	CbGbCtD
Pyrazinamide—Peptic ulcer—Vinblastine—germ cell cancer	0.00399	0.0392	CcSEcCtD
Pyrazinamide—Hepatomegaly—Dactinomycin—germ cell cancer	0.00297	0.0292	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Dactinomycin—germ cell cancer	0.00272	0.0267	CcSEcCtD
Pyrazinamide—Coagulopathy—Dactinomycin—germ cell cancer	0.0027	0.0265	CcSEcCtD
Pyrazinamide—Tubulointerstitial nephritis—Ifosfamide—germ cell cancer	0.00252	0.0247	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Ifosfamide—germ cell cancer	0.0025	0.0245	CcSEcCtD
Pyrazinamide—Coagulopathy—Ifosfamide—germ cell cancer	0.00247	0.0243	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Cisplatin—germ cell cancer	0.00215	0.0211	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Etoposide—germ cell cancer	0.00197	0.0193	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Cisplatin—germ cell cancer	0.00179	0.0176	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Cisplatin—germ cell cancer	0.00169	0.0166	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Etoposide—germ cell cancer	0.00164	0.0161	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Etoposide—germ cell cancer	0.00155	0.0152	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Etoposide—germ cell cancer	0.00138	0.0136	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Methotrexate—germ cell cancer	0.00118	0.0116	CcSEcCtD
Pyrazinamide—Dysuria—Ifosfamide—germ cell cancer	0.00113	0.0111	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Vinblastine—germ cell cancer	0.00108	0.0106	CcSEcCtD
Pyrazinamide—Hepatitis—Dactinomycin—germ cell cancer	0.00106	0.0104	CcSEcCtD
Pyrazinamide—Malaise—Vinblastine—germ cell cancer	0.00105	0.0103	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Methotrexate—germ cell cancer	0.000983	0.00965	CcSEcCtD
Pyrazinamide—Discomfort—Vinblastine—germ cell cancer	0.000982	0.00964	CcSEcCtD
Pyrazinamide—Hepatitis—Ifosfamide—germ cell cancer	0.000968	0.0095	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Vinblastine—germ cell cancer	0.000932	0.00915	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Methotrexate—germ cell cancer	0.000928	0.00911	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Bleomycin—germ cell cancer	0.000914	0.00898	CcSEcCtD
Pyrazinamide—Anorexia—Vinblastine—germ cell cancer	0.000908	0.00891	CcSEcCtD
Pyrazinamide—Malaise—Bleomycin—germ cell cancer	0.000889	0.00872	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Dactinomycin—germ cell cancer	0.000853	0.00837	CcSEcCtD
Pyrazinamide—Myalgia—Bleomycin—germ cell cancer	0.000839	0.00824	CcSEcCtD
Pyrazinamide—Discomfort—Bleomycin—germ cell cancer	0.000829	0.00814	CcSEcCtD
Pyrazinamide—Malaise—Dactinomycin—germ cell cancer	0.000829	0.00814	CcSEcCtD
Pyrazinamide—Decreased appetite—Vinblastine—germ cell cancer	0.000828	0.00813	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Bleomycin—germ cell cancer	0.000788	0.00773	CcSEcCtD
Pyrazinamide—Feeling abnormal—Vinblastine—germ cell cancer	0.000785	0.0077	CcSEcCtD
Pyrazinamide—Myalgia—Dactinomycin—germ cell cancer	0.000783	0.00768	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Ifosfamide—germ cell cancer	0.000781	0.00767	CcSEcCtD
Pyrazinamide—Discomfort—Dactinomycin—germ cell cancer	0.000773	0.00759	CcSEcCtD
Pyrazinamide—Anorexia—Bleomycin—germ cell cancer	0.000767	0.00753	CcSEcCtD
Pyrazinamide—Malaise—Ifosfamide—germ cell cancer	0.00076	0.00746	CcSEcCtD
Pyrazinamide—Photosensitivity—Methotrexate—germ cell cancer	0.000754	0.0074	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Dactinomycin—germ cell cancer	0.000734	0.00721	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Bleomycin—germ cell cancer	0.000733	0.00719	CcSEcCtD
Pyrazinamide—Arthralgia—Ifosfamide—germ cell cancer	0.000717	0.00704	CcSEcCtD
Pyrazinamide—Myalgia—Ifosfamide—germ cell cancer	0.000717	0.00704	CcSEcCtD
Pyrazinamide—Anorexia—Dactinomycin—germ cell cancer	0.000715	0.00702	CcSEcCtD
Pyrazinamide—Discomfort—Ifosfamide—germ cell cancer	0.000708	0.00696	CcSEcCtD
Pyrazinamide—Hypersensitivity—Vinblastine—germ cell cancer	0.000702	0.00689	CcSEcCtD
Pyrazinamide—Decreased appetite—Bleomycin—germ cell cancer	0.000699	0.00686	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	0.000683	0.00671	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Cisplatin—germ cell cancer	0.000674	0.00661	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Ifosfamide—germ cell cancer	0.000673	0.00661	CcSEcCtD
Pyrazinamide—Feeling abnormal—Bleomycin—germ cell cancer	0.000663	0.00651	CcSEcCtD
Pyrazinamide—Anorexia—Ifosfamide—germ cell cancer	0.000655	0.00643	CcSEcCtD
Pyrazinamide—Malaise—Cisplatin—germ cell cancer	0.000655	0.00643	CcSEcCtD
Pyrazinamide—Decreased appetite—Dactinomycin—germ cell cancer	0.000652	0.0064	CcSEcCtD
Pyrazinamide—Urticaria—Bleomycin—germ cell cancer	0.000639	0.00627	CcSEcCtD
Pyrazinamide—Body temperature increased—Bleomycin—germ cell cancer	0.000636	0.00624	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	0.000626	0.00615	CcSEcCtD
Pyrazinamide—Myalgia—Cisplatin—germ cell cancer	0.000618	0.00607	CcSEcCtD
Pyrazinamide—Feeling abnormal—Dactinomycin—germ cell cancer	0.000618	0.00607	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Etoposide—germ cell cancer	0.000617	0.00606	CcSEcCtD
Pyrazinamide—Discomfort—Cisplatin—germ cell cancer	0.000611	0.006	CcSEcCtD
Pyrazinamide—Vomiting—Vinblastine—germ cell cancer	0.000606	0.00594	CcSEcCtD
Pyrazinamide—Malaise—Etoposide—germ cell cancer	0.0006	0.00589	CcSEcCtD
Pyrazinamide—Decreased appetite—Ifosfamide—germ cell cancer	0.000598	0.00587	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Ifosfamide—germ cell cancer	0.000593	0.00583	CcSEcCtD
Pyrazinamide—Body temperature increased—Dactinomycin—germ cell cancer	0.000593	0.00582	CcSEcCtD
Pyrazinamide—Hypersensitivity—Bleomycin—germ cell cancer	0.000593	0.00582	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Cisplatin—germ cell cancer	0.00058	0.0057	CcSEcCtD
Pyrazinamide—Pruritus—Bleomycin—germ cell cancer	0.000569	0.00559	CcSEcCtD
Pyrazinamide—Feeling abnormal—Ifosfamide—germ cell cancer	0.000566	0.00556	CcSEcCtD
Pyrazinamide—Nausea—Vinblastine—germ cell cancer	0.000566	0.00555	CcSEcCtD
Pyrazinamide—Anorexia—Cisplatin—germ cell cancer	0.000565	0.00555	CcSEcCtD
Pyrazinamide—Discomfort—Etoposide—germ cell cancer	0.00056	0.00549	CcSEcCtD
Pyrazinamide—Hypersensitivity—Dactinomycin—germ cell cancer	0.000553	0.00543	CcSEcCtD
Pyrazinamide—Urticaria—Ifosfamide—germ cell cancer	0.000546	0.00536	CcSEcCtD
Pyrazinamide—Body temperature increased—Ifosfamide—germ cell cancer	0.000543	0.00533	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Cisplatin—germ cell cancer	0.00054	0.0053	CcSEcCtD
Pyrazinamide—Dysuria—Methotrexate—germ cell cancer	0.000535	0.00525	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Etoposide—germ cell cancer	0.000532	0.00522	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Methotrexate—germ cell cancer	0.000522	0.00512	CcSEcCtD
Pyrazinamide—Anorexia—Etoposide—germ cell cancer	0.000518	0.00508	CcSEcCtD
Pyrazinamide—Decreased appetite—Cisplatin—germ cell cancer	0.000515	0.00506	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Cisplatin—germ cell cancer	0.000512	0.00502	CcSEcCtD
Pyrazinamide—Vomiting—Bleomycin—germ cell cancer	0.000511	0.00502	CcSEcCtD
Pyrazinamide—Rash—Bleomycin—germ cell cancer	0.000507	0.00498	CcSEcCtD
Pyrazinamide—Dermatitis—Bleomycin—germ cell cancer	0.000507	0.00497	CcSEcCtD
Pyrazinamide—Hypersensitivity—Ifosfamide—germ cell cancer	0.000506	0.00497	CcSEcCtD
Pyrazinamide—Feeling abnormal—Cisplatin—germ cell cancer	0.000488	0.00479	CcSEcCtD
Pyrazinamide—Pruritus—Ifosfamide—germ cell cancer	0.000486	0.00477	CcSEcCtD
Pyrazinamide—Nausea—Bleomycin—germ cell cancer	0.000478	0.00469	CcSEcCtD
Pyrazinamide—Vomiting—Dactinomycin—germ cell cancer	0.000477	0.00468	CcSEcCtD
Pyrazinamide—Rash—Dactinomycin—germ cell cancer	0.000473	0.00464	CcSEcCtD
Pyrazinamide—Decreased appetite—Etoposide—germ cell cancer	0.000472	0.00463	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Etoposide—germ cell cancer	0.000469	0.0046	CcSEcCtD
Pyrazinamide—Body temperature increased—Cisplatin—germ cell cancer	0.000468	0.0046	CcSEcCtD
Pyrazinamide—Hepatitis—Methotrexate—germ cell cancer	0.000458	0.00449	CcSEcCtD
Pyrazinamide—Feeling abnormal—Etoposide—germ cell cancer	0.000447	0.00439	CcSEcCtD
Pyrazinamide—Nausea—Dactinomycin—germ cell cancer	0.000446	0.00437	CcSEcCtD
Pyrazinamide—Vomiting—Ifosfamide—germ cell cancer	0.000437	0.00429	CcSEcCtD
Pyrazinamide—Hypersensitivity—Cisplatin—germ cell cancer	0.000437	0.00429	CcSEcCtD
Pyrazinamide—Rash—Ifosfamide—germ cell cancer	0.000433	0.00425	CcSEcCtD
Pyrazinamide—Dermatitis—Ifosfamide—germ cell cancer	0.000433	0.00425	CcSEcCtD
Pyrazinamide—Urticaria—Etoposide—germ cell cancer	0.000431	0.00423	CcSEcCtD
Pyrazinamide—Body temperature increased—Etoposide—germ cell cancer	0.000429	0.00421	CcSEcCtD
Pyrazinamide—Nausea—Ifosfamide—germ cell cancer	0.000408	0.00401	CcSEcCtD
Pyrazinamide—Hypersensitivity—Etoposide—germ cell cancer	0.0004	0.00393	CcSEcCtD
Pyrazinamide—Pruritus—Etoposide—germ cell cancer	0.000384	0.00377	CcSEcCtD
Pyrazinamide—Vomiting—Cisplatin—germ cell cancer	0.000377	0.0037	CcSEcCtD
Pyrazinamide—Rash—Cisplatin—germ cell cancer	0.000374	0.00367	CcSEcCtD
Pyrazinamide—Dermatitis—Cisplatin—germ cell cancer	0.000373	0.00366	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Methotrexate—germ cell cancer	0.00037	0.00363	CcSEcCtD
Pyrazinamide—Malaise—Methotrexate—germ cell cancer	0.000359	0.00353	CcSEcCtD
Pyrazinamide—Nausea—Cisplatin—germ cell cancer	0.000352	0.00346	CcSEcCtD
Pyrazinamide—Vomiting—Etoposide—germ cell cancer	0.000345	0.00339	CcSEcCtD
Pyrazinamide—Rash—Etoposide—germ cell cancer	0.000342	0.00336	CcSEcCtD
Pyrazinamide—Dermatitis—Etoposide—germ cell cancer	0.000342	0.00336	CcSEcCtD
Pyrazinamide—Arthralgia—Methotrexate—germ cell cancer	0.000339	0.00333	CcSEcCtD
Pyrazinamide—Myalgia—Methotrexate—germ cell cancer	0.000339	0.00333	CcSEcCtD
Pyrazinamide—Discomfort—Methotrexate—germ cell cancer	0.000335	0.00329	CcSEcCtD
Pyrazinamide—Nausea—Etoposide—germ cell cancer	0.000322	0.00317	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Methotrexate—germ cell cancer	0.000318	0.00313	CcSEcCtD
Pyrazinamide—Anorexia—Methotrexate—germ cell cancer	0.00031	0.00304	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Methotrexate—germ cell cancer	0.000296	0.00291	CcSEcCtD
Pyrazinamide—Dyspepsia—Methotrexate—germ cell cancer	0.000286	0.00281	CcSEcCtD
Pyrazinamide—Decreased appetite—Methotrexate—germ cell cancer	0.000283	0.00278	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Methotrexate—germ cell cancer	0.000281	0.00276	CcSEcCtD
Pyrazinamide—Feeling abnormal—Methotrexate—germ cell cancer	0.000268	0.00263	CcSEcCtD
Pyrazinamide—Urticaria—Methotrexate—germ cell cancer	0.000258	0.00254	CcSEcCtD
Pyrazinamide—Body temperature increased—Methotrexate—germ cell cancer	0.000257	0.00252	CcSEcCtD
Pyrazinamide—Hypersensitivity—Methotrexate—germ cell cancer	0.00024	0.00235	CcSEcCtD
Pyrazinamide—Pruritus—Methotrexate—germ cell cancer	0.00023	0.00226	CcSEcCtD
Pyrazinamide—Vomiting—Methotrexate—germ cell cancer	0.000207	0.00203	CcSEcCtD
Pyrazinamide—Rash—Methotrexate—germ cell cancer	0.000205	0.00201	CcSEcCtD
Pyrazinamide—Dermatitis—Methotrexate—germ cell cancer	0.000205	0.00201	CcSEcCtD
Pyrazinamide—Nausea—Methotrexate—germ cell cancer	0.000193	0.0019	CcSEcCtD
